Biomea Fusion Q1 FY26 net loss narrows to $12.4 million; cash falls to $45.1 million

• Biomea Fusion posted a net loss attributable to common stockholders of USD 12.4 million, narrowing from USD 29.3 million a year earlier; loss per share improved to USD 0.17 from USD 0.80.
• R&D expense fell to USD 9.1 million from USD 22.9 million, due to lower external costs and personnel-related spending tied to reduced headcount.
• G&A expense dropped to USD 3.7 million from USD 6.8 million, on lower personnel-related and corporate costs.
• Cash, cash equivalents and restricted cash declined to USD 45.1 million as of March 31, 2026; cash runway projected into first quarter of 2027.
• Chronic toxicology studies completed for icovamenib to support dosing beyond 12 weeks; Phase II T2D trials COVALENT-211 and -212 began dosing with 26-week topline data expected in Q4 2026, while Phase I BMF-650 obesity study remained on track for initial 28-day weight data in Q2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605111654PRIMZONEFULLFEED9717831) on May 11, 2026, and is solely responsible for the information contained therein.